Free Trial
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

Neoleukin Therapeutics logo
$9.67 -0.79 (-7.55%)
As of 04/3/2025

About Neoleukin Therapeutics Stock (NASDAQ:NLTX)

Key Stats

Today's Range
$9.37
$10.54
50-Day Range
$9.66
$21.53
52-Week Range
$2.03
$14.36
Volume
225,981 shs
Average Volume
50,104 shs
Market Capitalization
$90.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Remove Ads
Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity
See More Headlines

NLTX Stock Analysis - Frequently Asked Questions

Neoleukin Therapeutics' stock was trading at $22.86 at the start of the year. Since then, NLTX stock has decreased by 57.7% and is now trading at $9.67.
View the best growth stocks for 2025 here
.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its earnings results on Thursday, November, 4th. The company reported ($5.60) earnings per share for the quarter, meeting analysts' consensus estimates of ($5.60).

Shares of Neoleukin Therapeutics reverse split on the morning of Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), General Electric (GE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/04/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NLTX
Employees
90
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$11.08 per share
Price / Book
0.94

Miscellaneous

Free Float
9,250,000
Market Cap
$98.30 million
Optionable
No Data
Beta
1.11
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NLTX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners